Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation
暂无分享,去创建一个
Yanhong Li | He Zhao | Gang Li | Yiping Li | Jian Wang | Jian Pan | F. Fang | Shaoyan Hu | Yun-yun Xu | Xiao-juan Du | Zhiheng Li | Xing Feng | Wen-li Zhao | P. Xiao | Li-xiao Xu | Yanfang Tao | Li-chao Sun | Jun Lu | Lan Cao | Na-Na Wang | J. Ni | Yunyun Xu | Yi-ping Li | Fang Fang
[1] Yanhong Li,et al. Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation , 2014, Journal of Translational Medicine.
[2] Yu Zhao,et al. AML1–ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia , 2014, The FEBS journal.
[3] C Haferlach,et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes , 2013, Leukemia.
[4] K. Tsui,et al. Metallothionein 3: An androgen‐upregulated gene enhances cell invasion and tumorigenesis of prostate carcinoma cells , 2013, The Prostate.
[5] A. Samadani,et al. DNA Methylation and Cancer Development: Molecular Mechanism , 2013, Cell Biochemistry and Biophysics.
[6] F. Xing,et al. The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML) , 2013, BMC Medical Genetics.
[7] Yanhong Li,et al. Survivin selective inhibitor YM155 induce apoptosis in SK-NEP-1 Wilms tumor cells , 2012, BMC Cancer.
[8] J. Persson,et al. DNA methylation in ATRA-treated leukemia cell lines lacking a PML-RAR chromosome translocation. , 2012, Anticancer research.
[9] S. Armstrong,et al. Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. , 2012, Trends in immunology.
[10] F. Xing,et al. Analyzing the gene expression profile of pediatric acute myeloid leukemia with real-time PCR arrays , 2012, Cancer Cell International.
[11] A. Kohlmann,et al. Landscape of TET2 mutations in acute myeloid leukemia , 2012, Leukemia.
[12] S. Armstrong,et al. Targeting epigenetic programs in MLL-rearranged leukemias. , 2011, Hematology. American Society of Hematology. Education Program.
[13] Naimei Tang,et al. Akt, FoxO and regulation of apoptosis. , 2011, Biochimica et biophysica acta.
[14] Haojie Huang,et al. FOXO1: a potential target for human diseases. , 2011, Current drug targets.
[15] M. Monsalve,et al. The complex biology of FOXO. , 2011, Current drug targets.
[16] Zhao Wen Li,et al. Retinoic acid induces HL-60 cell differentiation via the upregulation of miR-663 , 2011, Journal of hematology & oncology.
[17] Feng Wang,et al. Metallothionein 3 attenuated the apoptosis of neurons in the CA1 region of the hippocampus in the senescence-accelerated mouse/PRONE8 (SAMP8). , 2011, Arquivos de neuro-psiquiatria.
[18] J. Koh,et al. Roles of zinc and metallothionein-3 in oxidative stress-induced lysosomal dysfunction, cell death, and autophagy in neurons and astrocytes , 2010, Molecular Brain.
[19] T. Fukagawa,et al. KRAB zinc finger protein ZNF382 is a proapoptotic tumor suppressor that represses multiple oncogenes and is commonly silenced in multiple carcinomas. , 2010, Cancer research.
[20] R. Chung,et al. Neuronal growth‐inhibitory factor (metallothionein‐3): evaluation of the biological function of growth‐inhibitory factor in the injured and neurodegenerative brain , 2010, The FEBS journal.
[21] D. Tindall,et al. FOXOs, cancer and regulation of apoptosis , 2008, Oncogene.
[22] V. Schramm,et al. A Transition State Analogue of 5′-Methylthioadenosine Phosphorylase Induces Apoptosis in Head and Neck Cancers* , 2007, Journal of Biological Chemistry.
[23] S. Koschmieder,et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. , 2007, Cancer research.
[24] J. Issa,et al. PML-RARα and AML1–ETO translocations are rarely associated with methylation of the RARβ2 promoter , 2006, Annals of Hematology.
[25] B. Aronow,et al. beta-Catenin/Wnt signaling regulates expression of the membrane type 3 matrix metalloproteinase in gastric cancer. , 2006, Cancer research.
[26] J. Issa,et al. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. , 2006, Annals of hematology.
[27] A. Ruszkiewicz,et al. Metallothionien 3 expression is frequently down-regulated in oesophageal squamous cell carcinoma by DNA methylation , 2005, Molecular Cancer.
[28] Amornpan Ajjimaporn,et al. Metallothionein provides zinc-mediated protective effects against methamphetamine toxicity in SK-N-SH cells , 2005, Brain Research Bulletin.
[29] R. Palmiter,et al. Role of metallothionein-III following central nervous system damage , 2003, Neurobiology of Disease.
[30] R. Jaenisch,et al. Induction of Tumors in Mice by Genomic Hypomethylation , 2003, Science.
[31] J. Ji,et al. Hypermethylation of metallothionein-3 CpG island in gastric carcinoma. , 2003, Carcinogenesis.
[32] Rakesh Nagarajan,et al. FOXO Proteins Regulate Tumor Necrosis Factor-related Apoptosis Inducing Ligand Expression , 2002, The Journal of Biological Chemistry.
[33] M. Bartolomei,et al. Epigenetic reprogramming in the mammalian embryo: struggle of the clones , 2002, Genome Biology.
[34] P. Guldberg,et al. In-tube DNA methylation profiling by fluorescence melting curve analysis. , 2001, Clinical chemistry.
[35] M. Toyota,et al. Methylation profiling in acute myeloid leukemia. , 2001, Blood.
[36] C. Willman. Targeted AML therapy: new biologic paradigms and therapeutic opportunities , 2001, Leukemia.
[37] M. Loda,et al. Forkhead Transcription Factors Are Critical Effectors of Cell Death and Cell Cycle Arrest Downstream of PTEN , 2000, Molecular and Cellular Biology.
[38] E. Estey,et al. NCCN Practice Guidelines for Acute Myelogenous Leukemia. , 2000, Oncology.
[39] Rudolf Jaenisch,et al. DNA hypomethylation leads to elevated mutation rates , 1998, Nature.
[40] A. Olek,et al. A modified and improved method for bisulphite based cytosine methylation analysis. , 1996, Nucleic acids research.
[41] M. Sanz,et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. , 1989, Blood.